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Abstract – Acute kidney injury (AKI) is a
common complication associated with
cardiac surgery. Those patients who
develop AKI have increased hospital costs,
hospital LOS and odds of death. The current
diagnostic criteria rely on serum creatinine
measurements and urine output data.
Serum creatinine is not renal specific. It is
known that there are other factors that
influence serum creatine concentrations
other than renal injury. Serum creatinine
levels are measured as concentrations
which means large changes in fluid balance
may
alter
the
serum
creatinine
measurement. Urine output is not a reliable
measurement of renal injury either. During
surgery it is common to administer diuretics
which influence urine output independent
of renal damage. Researchers are
investigating novel biomarkers that are
renal specific and can monitor AKI risk in
real time. Some researchers are focused on
identifying chemical biomarkers to
diagnose AKI more effectively. Preliminary
studies have also shown that urine oxygen
concentration may be a physiological
biomarker that can be used to monitor AKI
risk in real time. Urine oxygen
concentration may reflect tissue oxygen
concentration in the medullary region of the
kidney. The aim of this study was to
investigate the relationship between urine
biomarker concentrations, urine oxygen
concentration and AKI diagnosis. The
results from this study suggest that is
possible to monitor oxygen concentration
non-invasively and it could potentially be
used to monitor AKI risk in real time.

INTRODUCTION AND BACKGROUND
Acute kidney injury (AKI) occurs in
approximately 30% off all patients who
undergo cardiac surgery.1 AKI is described by
an acute decrease in renal function and is
associated with decreased urine output and
excess metabolites in the urine. One study
found that mild to moderate AKI increased
hospital length of stay (LOS), hospital
associated costs and risk of death.2 Severe
AKI, which requires renal replacement
therapy (RRT), is associated with mortality
rates as high as 50-90% and an 8-fold
increase in the risk of death.3,4 Based on
these data it is important to accurately
diagnose AKI and further investigate
therapies or treatments to protect patients
from developing this syndrome.
The definition of AKI has changed over time
as new standards and criteria have been
developed. The Acute Dialysis Quality
Initiative (ADQI) group was the first group to
develop a uniform diagnostic criterion,
which became known as the RIFLE criteria.
This standard uses a three tiered severity
system that is based on the subjects
glomerular filtration rate (GFR) or urine
output.5 In 2007 the Acute Kidney Injury
Network (AKIN) modified the RIFLE criteria
with the hope of creating a uniform standard
with higher sensitivity for detecting AKI. This
definition of AKI is based on an increase in
serum
creatinine
concentration
or
6
decreased urine output. A study from
Engleberger et. al found that significantly
more patients were diagnosed with AKI
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when using the AKIN criteria compared to
the RIFLE criteria.7 The most recent standard
has been set forth by Kidney Disease
Improving Global Outcomes (KDIGO) with
the goal of creating a universal standard that
could be uniformly applied to future
research studies. This new standard is based
on the previous RIFLE and AKIN criteria and
uses serum creatinine concentrations or
urine output data to diagnose patients with
AKI.8 While increased serum creatinine
concentrations and decreased urine output
have been associated with impaired renal
function, these markers are not perfect
indicators of renal injury because they are
influenced by factors other than kidney
function.
One study found that the half-life of creatine
dramatically increases when there is a 5 %
reduction in kidney function. This means
that serum creatinine levels may not rise
until several days after the initial renal
injury. This does not help prevent or mitigate
AKI, and shows that serum creatinine
concentrations can only be used as a
diagnostic tool.9 Because serum creatinine is
measured as a concentration it is affected by
changes in volume. This means that patients
who are given large amounts of fluid will
have
a
lower
serum
creatinine
concentration, independent of whether they
experienced renal injury. It is also known
that serum creatinine concentrations are
affected by certain drugs that alter the
concentration independent of renal injury or
damage.10
Another concern with using
serum creatinine as a measure of renal injury
is that the definitions for AKI require a
baseline measurement. If there is not a
baseline measurement it is often estimated
through various methods which require
assumptions about the patient’s health and
prior renal function.

The validity of urine output as a marker for
renal injury has also recently been
questioned. Some researchers argue that
the KDIGO urine output AKI definition has
not been validated, and that the definition is
too liberal. One study showed that those
patients who were under a threshold of 0.3
ml/kg/hr for 6 hours or longer had a higher
risk of death and need for dialysis.11 The
current criteria uses 0.5 ml/kg/hr as a
threshold. It is also important to consider
that urine output is affected by
administration of diuretics which are
commonly given during surgery. For these
reasons it is important to identify other
physiological biomarkers that are renal
specific, could be used to identify renal
injury and monitor AKI risk in real time.
Researchers have studied the role of
neutrophil gelatinase-associated lipocalin
(NGAL) as a potential biomarker for
diagnosing AKI. It has been reported that
following renal injury there is an increase in
uptake of NGAL, which gives researchers
hope that it can be used in place of the
conventional biomarkers currently used.12
Other studies have identified kidney injury
mocule-1 and interleukin-18 as biomarkers
that could potentially be used to detect
AKI.13 Studies have also been done to
determine if urine oxygen concentration can
be used a physical biomarker to detect AKI.
Several studies have shown that tissue
hypoxia is a final common pathway for
multiple forms of AKI.14 Even though the
kidneys receive 20-25% of the cardiac output
and only extract 10-20% of the oxygen
delivered to them they are susceptible to
hypoxia. This is because the medullary
region of the kidney accounts for
approximately 80% of the oxygen extraction
associated with the kidney and due to
complex oxygen conservation and delivery
mechanisms receives oxygen poor blood.15 It
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Figure 1 - An image of the device that was used to measure urine oxygen concentration and urine flow rate. The device was
placed between the end of the urinary catheter and the tubing that goes to the urine collection bag.

would be ideal to directly measure the tissue
oxygen concentration in the medullary
region of the kidney, however this is not
currently feasible in a clinical setting.
To identify a physiological biomarker to
better identify renal injury researchers have
investigated the relationship between urine
oxygen concentration and tissue oxygen
concentration in the medulla. The collection
of blood vessels known as the vasa recta run
parallel and lie near the urinary collecting
ducts in the medullary region. Pannabecker,
Datnzler and Thomas et al. showed that due
to this spatial relationship the urine oxygen
concentration approximated the tissue
oxygen concentration in the medullary
region of the kidney. In addition, Evans et al.
has demonstrated that it is feasible to
measure urinary oxygen concentration in
the bladder and that those who later
develop AKI spend more time below a
designated urinary oxygen concentration
threshold than those who do not develop
AKI.16 Other studies have shown that urinary
oxygen concentration may be a viable
surrogate measurement for monitoring
renal hypoxia.17–19

The goal of this research was to investigate
potential biomarkers that could be used to
monitor AKI risk and diagnose AKI
intraoperatively. A novel device that noninvasively measured urinary oxygen
concentration and urine flow rate was
developed. Identifying novel biomarkers
that could be used intraoperatively could
help mitigate or prevent the development of
AKI. It would also help researchers further
study different therapies and interventions
to mitigate or prevent surgery associated
AKI. Preventing surgery associated AKI
would improve surgical outcomes, save
people’s lives, and reduce costs associated
with hospital and ICU length of stay.
METHODS
After IRB approval and informed consent 38
patients scheduled for cardiothoracic
surgery were enrolled at University of Utah
Health Sciences. PuO2, temperature, and
urinary flow sensors were installed between
the urinary catheter and the tubing going to
the urinary collection bag. All sensors were
sampled at 1 Hz. The device was removed 24
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hours after the end of cardiopulmonary
bypass. After removal, each device was
calibrated according to a calibration
protocol.
The concentration of five urinary biomarkers
(NGAL, KIM-1, IL-18, MCP-1, YKL-40) were
measured at baseline (shortly after
placement of urinary catheter) and 12-hours
post cardiopulmonary bypass. For each
patient, the percent change from baseline
was calculated for each biomarker. A
percent change in the upper tertile for any
biomarker was defined as "subclinical AKI."
"Clinical AKI" was defined as meeting the
KIDGO criteria for AKI based on serum
creatinine measurements.4 Patients with
subclinical or clinical AKI, were in the AKI
group, patients with neither subclinical nor
clinical AKI were in the "No AKI" group.
An average calibration curve was calculated.
The calibration curve was applied to the raw
oxygen data to obtain oxygen concentration
measurements. The oxygen concentration
and urine flow signals were combined to
calculate the oxygen mass flow rate. The
average oxygen mass flow rate, average
oxygen concentration, and average urine
flow rate during cardiopulmonary bypass
were calculated for each patient in the “No
AKI” and “AKI” groups. When comparing the
means of two groups a two-tailed t-test was
used. Eleven patients were excluded from
the analysis because they were diagnosed
with clinical AKI before the procedure, they
required a non-latex urinary catheter, or
their baseline measurement for any of the
biomarkers was in the top ten percent

Figure 2 - The comparison of the average mass flow rate
for the AKI and No AKI group. The difference was
statistically significant (P = 0.019)

Figure 3 - The comparison of the average urine oxygen
concentration for the AKI and No AKI groups. There was
not a statistically significant difference between the
groups.

RESULTS
The average oxygen mass flow rate (mean ±
SD) for the AKI group (n=12) was 337.62 ±
238.57 g/hr. For the No AKI group (n=14) the
average rate was 669.18 ± 381.75 g/hr.

Figure 4 - The comparison of the average oxygen mass
flow rate for the AKI, Subclinical AKI, and the Subclinical
and Clinical AKI groups. Those who had both forms of AKI
had the lowest average oxygen mass flow rate.
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Patients diagnosed with AKI had a
statistically significant lower average oxygen
mass flow rate than those who were not
diagnosed with AKI (p = 0.019, figure 2).
There was not a statistically significant
difference between the average oxygen
concentration for the AKI and No AKI groups
(figure 3).
Subjects who had both clinical and
subclinical AKI had a lower oxygen mass flow
rate compared to the other groups. Those
subjects with only subclinical AKI had a lower
oxygen mass flow rate than those who did
not have AKI (figure 4).
DISCUSSION
AKI is common complication associated with
cardiac surgery. Those who develop AKI have
increased risk of death and hospital LOS.
Current diagnostic criteria are based on
serum creatinine concentrations and urine
output data. These measures are insufficient
because they are not renal specific and can
only be used for diagnostic purposes after
the surgery is complete. Researchers are
focused on identifying novel biomarkers to
detect AKI intraoperatively. Many studies
have shown that certain chemical
biomarkers such as NGAL, KIM-1 and IL-18
have potential to detect AKI much earlier
than the current methods. Preliminary
research also shows that measuring urine
oxygen concentration in the bladder may be
a viable alternative to monitoring renal
hypoxia which is associated with increased
risk of developing AKI. The purpose of this
study was to investigate the relationship
between several different biomarkers, urine
oxygen tension outside the body and AKI
diagnosis.
This study showed the it is possible to
measure urine oxygen concentration outside
the body and that it could potentially be

used to monitor renal hypoxia. However,
based on the urine oxygen concentration
data and previously published research
there are other factors that confound the
oxygen concentration measurement. As the
urine travels through the ureter, into the
bladder and then through the urinary
catheter to our device outside the body
oxygen may diffuse in or out of the urine.
The quantity of oxygen that diffuses in or out
of the urine is likely dependent on the urine
flow rate. Future models may help account
for the oxygen diffusion which currently
confounds the signal.
In addition, this study showed that there are
biomarkers that are more sensitive than
creatinine for detecting renal injury.
Creatinine is not renal specific and therefore
may not be specific enough to detect all
cases of renal injury. Another advantage to
using these biomarkers is that may detect
AKI sooner than current methods.
Limitations of this study include the
population size and the definition of AKI.
Clinical AKI was defined only using serum
creatinine concentration and not urine
output. It has been shown that urine output
is associated with AKI diagnosis so future
work should include urine output in the AKI
diagnosis. Subclinical AKI was an arbitrary
definition and further research is needed to
determine
appropriate
cutoffs
for
diagnosing AKI.
CONCLUSION
In summary, the current methods for
detecting AKI are not renal specific and
cannot be used as a diagnostic tool in real
time. To prevent AKI, it is important to
detect AKI risk in real time. Urine oxygen
concentration and chemical biomarkers are
two potential methods that could be used to
monitor AKI risk. However, more research is
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needed to validate preliminary results and
refine
the
technology
to
obtain
measurements that reflect medullary tissue
oxygen concentration.
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